Novo Nordisk’s $9 B Bid for Metsera Marks Sharp Shift in Obesity-Drug Strategy

Novo Nordisk has launched a surprise $9 billion (£7.1 billion) bid to acquire Metsera, upending an earlier deal with Pfizer and signalling a major strategic push into the obesity drug market. 

Under its new leadership, Novo’s urgent move shows the Danish drugmaker is now adopting a more aggressive posture after losing ground to Eli Lilly in weight-loss treatments. 

Novo’s bid challenges Pfizer’s existing $7.3 billion deal with Metsera and gives Pfizer just four business days to counter. 

Experts say this bold acquisition attempt highlights how crucial the obesity-drug market has become — possibly worth up to $150 billion annually by 2030. 

While some analysts warn Novo may be paying a high price, the company is signalling it is willing to take risks to protect its future growth.